Hepatocellular Carcinoma (HCC) is the third most common cancer in men
and the sixth most common cancer in women. Berberis aristata, Andrographis paniculata, and
Thevetia peruviana are recognised for their significant roles as herbal medicines in traditional systems
and for their potential anticancer properties as a polyherbal combination (PHC). This research
addresses the gap by evaluating the efficacy of PHC and its nanoparticles relative to the standard
drug Sorafenib, offering insights into their potential as adjuvant therapies for HCC.
Eight groups of rats were established. Diethylnitrosamine (DEN) (initiator) followed by
CCl4 (promoter) was used to assess carcinogenicity. Treatment with Berberis aristata, Andrographis
paniculata, and Thevetia peruviana, along with their PHC (2:1:1) and prepared chitosan nanoparticles,
was given. Sorafenib was used as the standard in this study. Biochemical parameters, lipid
peroxidation, total bilirubin, total protein, albumin, globulin, and cancer biomarkers were assessed,
followed by a histopathological study.
Biochemical parameters, antioxidant parameters, LPO, total bilirubin, total protein, albumin,
globulin, and cancer biomarkers were found to be very highly significant (P<0.001) when
compared with the HCC group. However, histopathological studies showed normal cytoplasm
shape, reduced number of binucleated cells, and hepatic tissue restoration with altered hepatocytes
in the CNP-EL-treated group.
These plants contain bioactive components, notably berberine, andrographolide, and
rosmarinic acid, which have been explored for their therapeutic and pharmacological importance.
These findings suggest that the developed Polyherbal combination (2:1:1) and its
prepared nanoparticles exhibit chemopreventive effects against HCC and could be used as adjuvant
therapy.
S. Parveen, T. Mahmood, Anuradha Mishra et al.· Current Chemical Biology· 0 citations
Exosomes represent a promising class of naturally produced nanoparticles that exist at the nanoscale and carry a negative surface charge under physiological conditions. These tiny membranebound vesicles are released by cells throughout the body and function as biological messengers, transporting various molecular cargos between cells and facilitating critical cell-to-cell communication pathways. Existing therapies for neurodegenerative disorders face two critical barriers: they cannot precisely target the affected brain areas, and the blood-brain barrier blocks most potential treatments from entering the brain. Exosomes offer a promising solution to these challenges. Unlike most synthetic drug delivery systems that struggle to penetrate the brain's protective barrier, these naturally derived nanocarriers exhibit an inherent capacity to traverse the blood-brain barrier. This unique property, combined with their capacity for efficient intracellular delivery of therapeutic payloads, positions exosomes as an exciting platform for transporting pharmaceutical agents to the affected neural tissues. Through strategic engineering and modification, these vesicles can be transformed into highly precise delivery vehicles capable of targeting specific organs, tissues, or even individual cell types. This review explores the therapeutic potential and drug delivery applications of exosomes in the management of major neurodegenerative disorders. This review provides an in-depth examination of exosome biogenesis, current isolation methodologies, and surface engineering strategies, while critically evaluating the strengths and limitations of each approach. In addition, this review summarizes the current preclinical models and provides an overview of ongoing clinical trials investigating exosome-based therapies for neurological disorders.
Sourin Bhukta, N. Palei, Vishakha Jaiswal et al.· CNS and Neurological Disorde...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
